Unicycive Therapeutics appoints Douglas Jermasek as Executive Vice President, Corporate Strategy



Posted: October 26, 2021 at 7:30 a.m. EDT|Update: 1 hour ago

LOS ALTOS, California, October 26, 2021 / PRNewswire / – Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney failure, today announced the appointment of Douglas jermasek as Executive Vice President, Corporate Strategy. In this role, Mr. Jermasek, a seasoned healthcare professional, will be responsible for Unicycive’s corporate and business strategy and business development activities.

Unicycive (PRNewsfoto / Unicycive Therapeutics Inc.)

Doug has spent most of his career focusing on drugs for the treatment of kidney disease.

“With a past healthcare career at some of the largest biopharmaceutical companies, Doug brings a wealth of experience to Unicycive,” said Shalabh Gupta, MD, CEO. “It is important to note that he has spent the majority of his career focusing on kidney disease, where his responsibilities included portfolio development and lifecycle management strategy through the alignment of the activities of marketing, R&D and business development. We are delighted to have him join our team and look forward to his contributions. “

Mr. Jermasek has over 25 years of experience in the biopharmaceutical industry. Most recently, he was Senior Vice President, Marketing and Strategy at Akebia Therapeutics, a role he assumed following the merger with Keryx Biopharmaceuticals. He spent over a decade at Genzyme (a Sanofi company) culminating in senior vice president and general manager, responsible for the global renal business unit. In this role, he led the sales of over $ 1 billion, establishing Renvela® as the standard of care for the treatment of hyperphosphatemia in patients with chronic kidney disease (CRF) and achieve “blockbuster” status globally.1 Mr. Jermasek was also head of North America at Intercept Pharmaceuticals and held senior positions at Prometheus Laboratories, Agouron Pharmaceuticals and Abbott Laboratories. He holds a Masters of Business Administration and a Bachelor of Science in Biological Sciences from Brigham Young University.

Commenting on his appointment, Mr. Jermasek said: “I am delighted to join the Unicycive team whose mission is to make a meaningful difference in the lives of patients with kidney disease. While I am proud of my past accomplishments in this area, I am also touched by the challenges that remain and know that more can be done to improve patient outcomes and quality of life. I look forward to bringing my sales, business development and portfolio management expertise to support this important work.

About Unicycive

Unicycive is a biotechnology company developing new treatments for kidney disease. Unicycive’s flagship drug, Renazorb, is a new phosphate binding agent in development for the treatment of hyperphosphatemia. UNI-494 is a new, patent-protected chemical entity in advanced preclinical development for the treatment of acute kidney injury. For more information, please visit www.unicycive.com.

Forward-looking statement

Certain statements contained in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as “anticipate”, “believe”, “anticipate”, “estimate”. “And” intend “or other similar words or expressions regarding Unicycive’s expectations, strategy, plans or intentions. These forward-looking statements are based on Unicycive’s current expectations and actual results could may differ materially. Several factors could cause actual events to differ materially from those indicated by these forward-looking statements. These factors include, but are not limited to, clinical trials involve a lengthy and expensive process with uncertain outcome, and results of previous studies and trials may not be predictive of future trial results; our clinical trials may be suspended or discontinued due to unexpected side effects or other safety risks which could prevent the approval of our product candidates; risks associated with business disruptions, including the COVID-19 coronavirus outbreak, which could seriously harm our financial situation and increase our costs and expenses; dependence on key personnel; significant competition; uncertainties in patent protection and litigation; dependence on third parties; and risks associated with failure to obtain FDA clearances or approvals and failure to comply with FDA regulations. Investors should read the risk factors set out in our registration statement on Form S-1 and our periodic reports filed with the Securities and Exchange Commission. Although the list of factors presented here is considered representative, none of these lists should be taken as a complete statement of all potential risks and uncertainties. Factors not listed may present additional material barriers to making forward-looking statements. The forward-looking statements included herein are made as of the date hereof, and Unicycive assumes no obligation to publicly update such statements to reflect subsequent events or circumstances.

1Renvela® (sevelamer carbonate) is a registered trademark of Sanofi

View original content to download multimedia:

SOURCE Unicycive Therapeutics, Inc.

The above press release has been provided courtesy of PRNewswire. The views, opinions and statements contained in the press release are not endorsed by Gray Media Group and do not necessarily state or reflect those of Gray Media Group, Inc.


Leave A Reply

Your email address will not be published.